Skip to Main Content

We’re excited to announce the launch of several new (free!) newsletters.

Daily Recap, which arrives in your inbox weekdays at 4 p.m., keeps you on top of all the news in health and science, from the lab bench to the presidential campaign trail.

Weekend Reads, delivered Saturday mornings, compiles the best multimedia and text stories from STAT.


Pulse of Longwood, debuting tomorrow, will be your weekly guide to a bustling hub of top-ranked hospitals and biomedical research. Reporter Melissa Bailey will give you on-the-ground insight into the challenges facing hospitals, medical schools, and research labs; we hope it will be of interest far beyond Boston.

And we’ll soon roll out a daily newsletter on the drug industry by Pharmalot columnist Ed Silverman.


Please sign up for these newsletters here.

I’m also pleased to introduce you to our newest biotech reporter, Damian Garde. Most recently the executive editor for Fierce Biotech, Damian joins us with a mandate to dive deep into the world of drug development in Kendall Square and beyond. Watch for his new Kendall Squared newsletter later this spring. (And in the meantime, catch up on our podcast Signal, hosted by veteran biotech reporters Meg Tirrell and Luke Timmerman.)

On the (much) lighter side, today we’re launching a fun video series, Boddities, in which reporter Megan Thielking answers questions about all the weird ways the human body works. You won’t want to miss the first episode about the best way to settle a queasy stomach.  (Don’t worry, Megan will continue to write our flagship newsletter, Morning Rounds.)

If you’re craving more from our multimedia team, check out the first installment of our “Day in the Life” series, in which video journalist Dom Smith chronicles the chaos a helicopter medic encounters in the skies.

We hope you enjoy these new features.

One final note: STAT recently went to court in an effort to unseal documents that could provide new information on how Purdue Pharma marketed its potent pain pill OxyContin — including what top executives knew about the drug’s addictive qualities and whether they downplayed those risks. A hearing is scheduled for next month. We have a lot of goals for STAT, but among our most important is to serve as a watchdog, pressing to uncover information that could shape the public debate. We believe the Purdue documents could shed light on the opioid crisis that’s affecting so many, and we’ll keep you up to date on our legal fight to make them public.

Always, we encourage your input and thoughts as STAT evolves.